| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Departments of Neuro-Oncology [S-A. I., C. G-M., J. F., T-J. L., L. D. K., J-S. K., P. A. S., A. P. K., W. K. A. Y.] and Head and Neck Medical Oncology [H-Y. L.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
VEGF carried the coding sequence of wild-type VEGF165 cDNA in an antisense orientation. Infection of U-87 MG malignant glioma cells with the Ad5CMV-VEGF resulted in reduction of the level of the endogenous VEGF mRNA and drastically decreased the production of the targeted secretory form of the VEGF protein. Treatment of s.c. human glioma tumors established in nude mice with intralesional injection of Ad5CMV-VEGF inhibited tumor growth. Taken together, these findings indicate that the efficient down-regulation of the VEGF produced by tumoral cells using antisense strategies has an antitumor effect in vivo. This is the first time that an adenoviral vector is used to transfer antisense VEGF sequence into glioma cells in an animal model, and our results suggest that this system may have clinical and therapeutic utility. |
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Increasing knowledge of molecular concepts has yielded a battery of potential therapies for cancer, but the clinical application of these methods has not been completely successful. This is in part because in vitro models used for screening often do not duplicate in vivo conditions. In this regard, proof of the role of VEGF in tumor angiogenesis requires the demonstration that inhibition of VEGF action prevents tumor growth in vivo. In the study we describe here, an adenovirus (Ad5CMV-VEGF) was used to transfer antisense VEGF165 cDNA into a human malignant glioma cell line, with the result that the exogenous sequence was efficiently transferred and highly expressed. After the treatment of glioma cells, production of the endogenous VEGF165 mRNA and production of the secretory VEGF protein levels were both decreased. The availability of an adenovirally mediated system capable of blocking VEGF message in vitro allowed us to test the hypothesis directly in vivo. Treatment of human glioma tumors implanted s.c. in nude mice with the Ad5CMV-VEGF resulted in consistent suppression of growth. To our knowledge, this is the first time that a recombinant adenovirus has been used to down-regulate VEGF in human gliomas. In addition, our in vivo results suggest that a brain tumor treatment based on antisense VEGF strategies may be feasible and effective.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
VEGF).
Construction and Generation of the Adenoviral Vectors.
To down-regulate endogenous VEGF expression and enhance the in vivo applicability of the antisense VEGF strategy, we constructed a replication-deficient recombinant adenoviral vector containing the cDNA for VEGF165 in an antisense orientation (Fig. 1A)
following a procedure described previously (9)
. The expression plasmid pXCL-CMV-VEGF was cotransfected with the plasmid pJM17 (10)
into the transformed human embryonic kidney cell line 293 cells (American Type Culture Collection, Rockville, MD) by calcium phosphate method. Homologous recombination of the expression plasmid and pJM17 in 293 cells replaced the E1 region with the expression cassette from the expression plasmid. After cotransfection, individual viral plaques were isolated. Plaques containing the human VEGF165 cDNA were identified by the PCR and restriction enzyme digestion. Then, these plaques were amplified in 293 cells. Ad5(dl312), an E1-deleted adenovirus type 5 carrying no exogenous gene, was used as an adenoviral control vector (11)
. Ad5CMV-VEGF, Ad5(dl312), and Ad5CMV-LacZ were propagated in 293 cells and then underwent CsCl density purification. Subsequently, the preparations were dialyzed and stored in the dialysis buffer (10 mmol/l Tris-HCl and 1 mmol/l MgCl2, pH 7.4) with 10% glycerol at -80°C. The titer of each viral stock was determined in 293 cells by plaque assays (12)
.
|
Human Glioma Cell Line and Tissue Culture Conditions.
The human glioma cell line U-87 MG was obtained from the American Type Culture Collection. U-87 MG cells were maintained in DMEM/Ham’s F-12 medium (1:1, v/v) supplemented with 10% fetal bovine serum in a humidified atmosphere containing 5% CO2 at 37°C. The 293 cells were maintained in high-glucose DMEM with 10% heat-inactivated fetal bovine serum.
Determination of Transduction Efficiency.
Ad5CMV-LacZ was used to infect the U-87 MG cells (105 cells/well) in six-well plates at different MOIs, further defined as the ratio of the number of infectious virions to the number of susceptible cells, ranging from 5 to 100. Forty-eight h later, cells were fixed with 4% paraformaldehyde in a phosphate-buffered NaCl solution at 4°C for 5 min, washed with the phosphate-buffered NaCl solution, and then stained with 1 mg/ml 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside in 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 2 mM MgCl2 in phosphate-buffered NaCl solution at 37°C overnight. The percentage of ß-galactosidase-positive cells, or the infection efficiency, was determined by scoring the number of blue cells among 500 cells each on replicate dishes.
Northern Blot Analyses.
U-87 MG cells at a density of 2 x 106 were seeded onto a 15-cm plate and allowed to adhere overnight. The next day, the cells were infected with Ad5CMV-VEGF at 50 MOI. The total cellular RNA was isolated 1, 2, 3, 4, and 5 days after infection by the acid-guanidinium thiocyanate method, as described previously (14)
. Dose/effect experiments were performed as follows. U-87 MG cells at a density of 2 x 106 were seeded onto a 15-cm plate and allowed to adhere overnight. The next day, the cells were infected with either Ad5CMV-VEGF or Ad5(dl312) at five different MOIs (25, 50, 100, 200, and 400). Three days after infection, the total cellular RNA was isolated. For the Northern analysis, 15 µg of total cellular RNA prepared from each sample were subjected to electrophoresis on a 1% agarose gel containing 2% formaldehyde, stained with ethidium bromide, photographed, transferred to a nylon membrane (Zetaprobe; Bio-Rad Laboratories, Hercules, CA), and hybridized to an [-32P]dCTP-labeled VEGF165 cDNA probe. Random priming was performed using the Prime It kit (Stratagene, La Jolla, CA), after which the membrane was washed in high-stringency conditions and autoradiographed for 5 h.
ELISA.
We performed human VEGF ELISA analyses to quantitate the secretory VEGF165 in conditioned medium according to the manufacturer’s protocol (R & D Systems, Minneapolis, MN). To prepare the conditioned medium, 105 cells were seeded overnight on six-well plates with medium containing 10% serum. Then, cells were infected with either Ad5CMV-VEGF or Ad5(dl312) at different MOIs. Culture medium was used for the mock infection. Triplicate dishes of cells subjected to each treatment were used. Conditioned media were processed 3, 6, and 9 days after infection. Thirty h before collecting conditioned media, the cells were washed three times with 2 ml of serum-free medium/well. After which the cells were preconditioned by incubation in 2 ml of serum-free medium/well for 6 h. After the preconditioned medium was aspirated, the cells were washed again with 2 ml of serum-free medium/well and incubated for 24 h in 1 ml of medium containing 2% serum. The medium was collected in a tube containing 1 µl of 100 mM phenylmethylsulfonyl fluoride.
The bFGF ELISA was performed according to the manufacturer’s protocol (R & D System) using total cellular lysate and conditioned medium. Total cell lysates for bFGF ELISA were prepared by incubating the cells at 3, 6, and 9 days after infection in radioimmumoprecipitation assay buffer (150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 20 mM EDTA, and 50 mM Tris, pH 7.4) for 1 h at 4°C. Conditioned medium for bFGF ELISA was prepared following the procedures described above for VEGF ELISA.
Determination of the Cell Growth Rate in Vitro.
U-87 MG glioma cells were seeded at a density of 104 cells/well in six-well culture plates and allowed to adhere overnight. The next day, the cells were infected with either Ad5CMV-VEGF or Ad5(dl312) at an MOI of 100 or plain medium. Triplicate dishes of each treatment were counted at regular intervals until the 12th day after infection. The population doubling level was calculated using the following formula: 
(where Nh = cell harvest number, N i =cell inoculum number, and X = number of population doubling).
Ad5CMV-VEGF Treatment in Vivo.
The animal study was carried out at the animal facility of M. D. Anderson Cancer Center in accordance with institutional guidelines. In this study, athymic female nu/nu mice, 4–6 weeks of age, were acclimated and caged in groups of five or fewer. All mice were fed a diet of animal chow and water ad libitum. The animals were anesthetized with methoxyflurane before all procedures and were observed until fully recovered. U-87 MG cells (107) in 100 µl of serum-free medium were injected s.c. into the flank of the nude mouse. By 4 days, visible and palpable s.c. nodules had developed at all injection sites. Intratumoral treatment with serum-free medium or 109 PFUs of either Ad5(dl312) or Ad5CMV-VEGF (eight mice/group) was started and repeated every other day for a total of four times. At the end of the measurement period, the mice were sacrificed by a lethal dose of CO2, and their tumors were excised and fixed in neutral-buffered formalin for routine histological examination and H&E staining. To measure tumor volume, the largest (a) and smallest (b) diameters of each tumor were measured, and the volume was calculated by the formula: 
(15)
. The tumor volumes for the different treatment groups were compared using nonparametric Kruskal-Wallis one-way ANOVA using the SPSS/PC+software package (SPSS, Inc., Chicago, IL).
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
VEGF, containing the cDNA for VEGF165 in an antisense orientation (Fig. 1A)
. The extent of adenovirus gene transfer in a glioblastoma cell line was determined by measuring reporter gene expression 48 h after infection with Ad5CMV-LacZ at different MOIs. The transduction efficiency was shown by the percentage of blue cells seen after 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside staining. The transduction efficiencies of U-87 MG cells at 20 MOI was 78%, and the efficiency increased with higher MOIs, reaching >99% at 100 MOI (Fig. 1B)
.
Ad5CMV-VEGF Down-Regulated Endogenous mRNA VEGF165.
We decided to perform this study using an antisense VEGF165 cDNA for several reasons: (a) the transcript encoding the 165-amino acid species is the most abundant product of the VEGF gene; (b) VEGF165 and VEGF121 promote endothelial cell growth and are efficiently secreted by cells; and (c) VEGF165 cDNA contains the full sequence for the VEGF121 cDNA (4)
. In addition, the two larger forms, VEGF189 and VEGF206, are mostly cell associated, and media conditioned by stable cell lines expressing VEGF189 and VEGF206 have a very low level of mitogenic activity for endothelial cells. The human glioblastoma cell line, U-87 MG, was chosen for this study because this cell line expresses high levels of VEGF mRNA, secretes the VEGF protein, and expresses the four VEGF splice variants, including VEGF165 (7)
. In addition, these malignant glioma cells are able to form tumors in mice.
Northern blot analyses were performed to determine the level of endogenous VEGF mRNA expression. In this series of experiments, cells were treated with Ad5CMV-VEGF at 50 MOI, and then the total cellular RNA was isolated at different times (1–5 days) after infection. Maximal down-regulation of the endogenous VEGF mRNA was observed between 3 and 5 days after infection (Fig. 2A)
. To determine the influence of different MOIs, U-87 MG cells were infected with 25–400 MOIs, and the total cellular RNA was isolated 3 days after infection. The levels of the 4.3-kb, endogenous VEGF mRNA detected in the samples isolated from Ad5CMV-VEGF-infected cells were down-regulated 20% at 25 MOI (Fig. 2B
, Lane 2), and the degree of down-regulation increased with increasing MOIs (Fig. 2B
, Lanes 3–6). In particular, at 100 MOI, the endogenous VEGF mRNA was down-regulated by >50%, and at 200 MOI, the endogenous VEGF mRNA was almost undetectable. The levels of endogenous VEGF mRNA detected in the samples isolated from mock-infected cells (Fig. 2B
, Lane 1) and from Ad5(dl312)-infected cells (Fig. 2B
, Lanes 7–9) were similar. In addition, exogenous, 0.8-kb antisense VEGF mRNA was present in the cells infected with Ad5CMV-VEGF (Fig. 2B
, Lanes 2–6), indicating that the exogenous VEGF165 antisense cDNA was successfully transduced into these cells and then efficiently transcribed. The decreased levels of endogenous VEGF mRNA in the Ad5CMV-VEGF-infected cells are likely due to their antisense RNA-targeted degradation.
|
VEGF Treatment Induces a Reduction of the Expression Level of VEGF165 Protein.VEGF. The mock-infected and Ad5(dl312)-infected U-87 MG cells secreted VEGF protein at a concentration of 1451.7 ± 178.5 and 1468 ± 328.5 pg/ml/105 cells/24 h, 6 days after infection, respectively; Ad5CMV-VEGF-infected cells produced 888.7 ± 153.8 pg/ml/105 cells/24 h at 100 MOI (Fig. 2C)
. The effect of antisense VEGF on VEGF protein secretion was maximal at 9 days after infection. Secreted VEGF protein levels in Ad5CMV-VEGF-infected cells dropped to 654.5 ± 18.2 pg/ml/105 cells/24 h at 100 MOI, 9 days after infection (Fig. 2D)
.
To determine whether the Ad5CMV-VEGF is specific to VEGF, the expression of bFGF was studied by ELISA. ELISA of the cellular and conditioned media proteins were performed on days 3, 6, and 9 after adenoviral infection. Down-regulation of the bFGF was not observed, indicating that the Ad5CMV-VEGF effect is probably specific to VEGF (Fig. 3A)
.
|
VEGF-infected U-87 MG Cells Did Not Show Any Modification in the Growth Rate in Vitro.VEGF-infected U-87 MG cells as shown in Fig. 2
, we did not observe any reduction in the growth rate of Ad5CMV-VEGF-infected U-87 MG cells compared with that of mock- and Ad5(dl312)-infected U-87 MG cells in vitro, as shown by the fact that the population doubling levels of mock-, Ad5 (dl312)-, and Ad5CMV-VEGF-infected U-87 MG cells were 2.55, 2.62, and 2.42, respectively (Fig. 3B)
.
The Ad5CMV-VEGF Treatment Suppresses Tumor Growth in Vivo.
The U-87 MG (107) cells were injected s.c. into the flank of the nude mouse. By 4 days, visible and palpable s.c. nodules (mean size, 54.6 mm3) had developed at all injection sites. To determine the potential effectiveness of Ad5CMV-VEGF therapy, intratumoral treatment with serum-free medium or 109 PFU of either Ad5(dl312) or Ad5CMV-VEGF (eight mice/group) was started and repeated every other day for a total of four times. Four weeks later, tumor sizes were measured, and the mean tumor size was 977.2 ± 234.89 mm3 in the serum-free medium treatment group and 1475.6 ± 722.66 mm3 in the Ad5(dl312) treatment group. In contrast, tumor size in the Ad5CMV-VEGF treatment group was 236.3 ± 223.12 mm3. The difference between sizes of tumor in the control ant test groups was significant (P = 0.004; Fig. 4
), providing direct evidence that Ad5CMV-VEGF has an antitumoral effect in vivo. No gross adverse effect of this inoculation on the animals health and behavior was observed during experimental periods. Data from these animal experiments demonstrate that adenovirus-mediated antisense-VEGF gene transfer can suppress the growth of tumors derived from the human glioblastoma U-87 MG cells.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-2a, and angiostatin (16)
. The rationale for antiangiogenic therapy is that progressive tumor growth is angiogenesis dependent. This concept has recently been the subject of renewed interest in the development of new therapeutic strategies.
The present study describes the in vitro and in vivo effect of Ad5CMV-VEGF, a replication-deficient recombinant adenoviral vector that carries the cDNA for the human form of VEGF165 in an antisense orientation. Our data demonstrated that the transfer of an antisense cDNA in vitro efficiently down-regulates VEGF mRNA and secretory VEGF protein. In addition, the transfer of antisense VEGF cDNA did not result in the down-regulation of bFGF, another angiogenic factor unrelated to VEGF, which showed that the antisense effect is specific to VEGF and does not result from a nonspecific suppression of angiogenic factors. In addition, Ad5CMV-VEGF did not seem to have a direct effect on the tumor cells themselves, as demonstrated by the growth studies which showed that the adenoviral construct was unable to slow the growth of glioma cells in vitro. Our results also demonstrated that Ad5CMV-VEGF can be efficiently delivered in vivo and significantly suppresses the growth of preestablished tumor xenografts with reduction in the levels of VEGF, a finding consistent with the anticancer effect reported recently for other inhibitors of angiogenesis (17)
. This strategy exploits the ubiquity of tumor angiogenesis, which makes it a suitable target for therapy, as has been proposed previously to be an important concept for antitumor therapy (18)
. Taken together, the effect of the antisense treatment on the production of VEGF and tumor burden suggests that the anticancer mechanism of the Ad5CMV-VEGF stems from an antiangiogenic effect.
Our data also revealed that slowly growing endothelial cells, as opposed to rapidly dividing mutant glioma cells, may be an effective therapeutic target. Tumor cell resistance to cancer treatment is determined by, among other factors, the genetic abnormalities characteristic of the cancer cells. It is such genetic abnormalities specific to glioma cells, that, for example, make them resistant to apoptosis inducer treatments. Endothelial cells may be targeted indirectly through the down-regulation of a pivotal effector of their growth and proliferation. This is indicated by the fact that tumor-induced neovascularization appears to result from a homeostatic balance between the angiogenic stimulators and inhibitors produced by tumor cells and proliferating endothelial cells (1) . One of the angiogenic stimulators is the VEGF protein, a directly acting endothelial cell mitogen and angiogenesis inducer (4) . A significant body of evidence is accumulating that favors the notion that VEGF and its receptors play an important role in the development of solid tumors, such as those derived from glial cells. It is for this reason that specific monoclonal antibodies directed against VEGF dramatically inhibit the growth of a human tumor cell lines injected s.c. in nude mice (19) . In addition, we have published previously that VEGF can be down-regulated in glioma cells using ribozymes designed to target the VEGF sequence (20) . Other relevant experiments showed that the transfer of an antisense-VEGF to glioma cells reduces their ability to form tumors in nude mice (7 , 8) . Of further note, dominant-negative mutants that interfere with the normal function of the VEGF receptor, Flk-1, inhibit glioblastoma growth in vivo (21, 22, 23) .
Intratumoral therapy is of special interest in the treatment of brain tumors. The presence of the blood-brain barrier limited the use of systemic therapies for brain tumors. In this study, we showed that local administration of antisense-VEGF is enough to suppress tumor growth. This is of significance because angiogenesis, besides being a characteristic of malignancy in most solid tumors, is also a physiological process in some organs and constitutes a normal response to injury (4 , 24, 25, 26) . Our local approach to brain tumor treatment may therefore not only be effective but also free of the potential adverse effects of systemic antiangiogenesis. The downside of any intratumoral approach using adenovirus is the inability of current vectors to deliver the exogenous message to every tumor cell in vivo. The incomplete delivery of the antisense VEGF cDNA might be responsible for the lack of a complete anticancer effect. Thus, although we showed tumor inhibition, we did not observe tumor regression. One explanation for this fact is that noninfected cells can still release VEGF and induce angiogenesis. Future vectors able to infect the majority of the cells in vivo and multiple injections of the vector into the tumor may be necessary to improve the delivery of the antisense message and either induce tumor regression or inhibit tumor growth for a long period of time.
In summary, the present study shows the in vitro and in vivo effect of Ad5CMV-VEGF, a replication-deficient recombinant adenoviral vector that carries the cDNA for the human form of VEGF165 in an antisense orientation. Taken together, our data demonstrate that the cDNA encoding a secreted form of the VEGF can be efficiently delivered in vivo and significantly inhibits the growth of preestablished experimental tumors. Although several angiogenic mediators are involved in tumor angiogenesis, our finding that decreased levels of endogenous VEGF leads to significant tumor inhibition underscores the pivotal role of the VEGF system in tumor angiogenesis. Importantly, our data suggest that the Ad5CMV-VEGF may be a useful tool for successful vascular targeting to achieve directed and effective therapy for gliomas.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 This work was supported in part by NIH Grants CA-51148, CA-55261, and CA-16672 and a grant from the Gilliland Foundation. 
2 To whom requests for reprints should be addressed, at Department of Neuro-Oncology, Box 100, University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 794-1285; Fax: (713) 774-4999; E-mail: yung{at}utmdacc.mda.uth.tmc.edu
3 The abbreviations used are: VEGF, vascular endothelial growth factor; CMV, cytomegalovirus; Ad5CMV-VEGF, recombinant adenovirus 5 containing the coding sequence of the wild-type VEGF165 in an antisense orientation; MOI, multiplicity of infection; Ad5(dl312), E1-deleted, replication-defective adenovirus type 5; bFGF, basic fibroblast growth factor; PFU, plaque forming unit.
Received 8/27/98. Accepted 12/16/98.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  T. Inai, M. Mancuso, H. Hashizume, F. Baffert, A. Haskell, P. Baluk, D. D. Hu-Lowe, D. R. Shalinsky, G. Thurston, G. D. Yancopoulos, et al. Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts Am. J. Pathol., July 1, 2004; 165(1): 35 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Snowden, L. Zhang, F. Urnov, C. Dent, Y. Jouvenot, X. Zhong, E. J. Rebar, A. C. Jamieson, H. S. Zhang, S. Tan, et al. Repression of Vascular Endothelial Growth Factor A in Glioblastoma Cells Using Engineered Zinc Finger Transcription Factors Cancer Res., December 15, 2003; 63(24): 8968 - 8976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Jiang and J. R. Couchman Perlecan and Tumor Angiogenesis J. Histochem. Cytochem., November 1, 2003; 51(11): 1393 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Fine, P. Y. Wen, E. A. Maher, E. Viscosi, T. Batchelor, N. Lakhani, W. D. Figg, B. W. Purow, and C. B. Borkowf Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas J. Clin. Oncol., June 15, 2003; 21(12): 2299 - 2304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, D. Yu, D. J. Hicklin, J. A. F. Hannay, L. M. Ellis, and R. E. Pollock Combined Anti-Fetal Liver Kinase 1 Monoclonal Antibody and Continuous Low-Dose Doxorubicin Inhibits Angiogenesis and Growth of Human Soft Tissue Sarcoma Xenografts by Induction of Endothelial Cell Apoptosis Cancer Res., April 1, 2002; 62(7): 2034 - 2042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Maity, N. Pore, J. Lee, D. Solomon, and D. M. O’Rourke Epidermal Growth Factor Receptor Transcriptionally Up-Regulates Vascular Endothelial Growth Factor Expression in Human Glioblastoma Cells via a Pathway Involving Phosphatidylinositol 3'-Kinase and Distinct from That Induced by Hypoxia Cancer Res., October 1, 2000; 60(20): 5879 - 5886. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Ciardiello, R. Bianco, V. Damiano, G. Fontanini, R. Caputo, G. Pomatico, Sabino De Placido, A. R. Bianco, J. Mendelsohn, and G. Tortora Antiangiogenic and Antitumor Activity of Anti-Epidermal Growth Factor Receptor C225 Monoclonal Antibody in Combination with Vascular Endothelial Growth Factor Antisense Oligonucleotide in Human GEO Colon Cancer Cells Clin. Cancer Res., September 1, 2000; 6(9): 3739 - 3747. [Abstract] [Full Text]
|
|
|
|
|
|
H. Kiaris, A. V. Schally, A. Nagy, B. Sun, K. Szepeshazi, and G. Halmos Regression of U-87 MG Human Glioblastomas in Nude Mice after Treatment with a Cytotoxic Somatostatin Analog AN-238 Clin. Cancer Res., February 1, 2000; 6(2): 709 - 717. [Abstract] [Full Text]
|
|
|
|
|
|
M. Prewett, J. Huber, Y. Li, A. Santiago, W. O'Connor, K. King, J. Overholser, A. Hooper, B. Pytowski, L. Witte, et al. Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors Cancer Res., October 1, 1999; 59(20): 5209 - 5218. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
